Increased risk for vascular complications due to GP IIb/IIIa-antagonists in patients with cardiogenic shock supported by intraaortic balloon pump (IABP)

Jens Röther , Monique Tröbs, Annika Schuhbäck, Josef Ludwig, Stephan Achenbach, Christian Schlundt
{"title":"Increased risk for vascular complications due to GP IIb/IIIa-antagonists in patients with cardiogenic shock supported by intraaortic balloon pump (IABP)","authors":"Jens Röther ,&nbsp;Monique Tröbs,&nbsp;Annika Schuhbäck,&nbsp;Josef Ludwig,&nbsp;Stephan Achenbach,&nbsp;Christian Schlundt","doi":"10.1016/j.ctrsc.2015.08.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>IABP is routinely used to support coronary blood flow and systemic circulation in patients with cardiogenic shock. Our aim was to explore the incidence of vascular complications associated with the use of IABP in this scenario and their influence on mortality.</p></div><div><h3>Methods</h3><p>Therefor we analysed 204 consecutive patients between 2002 and 2013 treated with IAPB in cardiogenic shock for vascular complications and mortality within 30<!--> <!-->days after implantation of IAPB. Primary endpoints were severe bleeding (TIMI-definition: intracranial bleeding, loss of haemoglobin (Hb) &gt;<!--> <!-->5<!--> <!-->g/dl or haematocrit (PCV) &gt;<!--> <!-->15%), vascular complications with therapeutic consequence (venous thrombosis, arterial embolism) and stroke.</p></div><div><h3>Results</h3><p>80 (39%) patients died within 30<!--> <!-->days after implantation of IABP. In 42 (21%) patients, vascular complications occurred: severe bleeding was present in 26 patients (62% of all complications), 13 (31%) patients suffered from venous thrombosis or arterial embolism and 3 (7%) patients from stroke. 25% of the patients who died had a vascular complication. The rate in patients who overcame cardiogenic shock was 17.7% (<em>p</em> <!-->=<!--> <!-->0.22). Multivariate analyses showed treatment with Glycoprotein (GP) IIb/IIIa- inhibitors to be an independent risk factor for the occurrence of vascular complications (<em>p</em> <!-->=<!--> <!-->0.04).</p></div><div><h3>Conclusion</h3><p>Vascular events with the use of IABP are common but in our study, not significantly associated with a higher mortality. Treatment with GP IIb/IIIa-antagonists is associated with a higher risk of vascular events.</p></div>","PeriodicalId":91232,"journal":{"name":"Clinical trials and regulatory science in cardiology","volume":"8 ","pages":"Pages 1-3"},"PeriodicalIF":0.0000,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrsc.2015.08.008","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical trials and regulatory science in cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405587515300081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

IABP is routinely used to support coronary blood flow and systemic circulation in patients with cardiogenic shock. Our aim was to explore the incidence of vascular complications associated with the use of IABP in this scenario and their influence on mortality.

Methods

Therefor we analysed 204 consecutive patients between 2002 and 2013 treated with IAPB in cardiogenic shock for vascular complications and mortality within 30 days after implantation of IAPB. Primary endpoints were severe bleeding (TIMI-definition: intracranial bleeding, loss of haemoglobin (Hb) > 5 g/dl or haematocrit (PCV) > 15%), vascular complications with therapeutic consequence (venous thrombosis, arterial embolism) and stroke.

Results

80 (39%) patients died within 30 days after implantation of IABP. In 42 (21%) patients, vascular complications occurred: severe bleeding was present in 26 patients (62% of all complications), 13 (31%) patients suffered from venous thrombosis or arterial embolism and 3 (7%) patients from stroke. 25% of the patients who died had a vascular complication. The rate in patients who overcame cardiogenic shock was 17.7% (p = 0.22). Multivariate analyses showed treatment with Glycoprotein (GP) IIb/IIIa- inhibitors to be an independent risk factor for the occurrence of vascular complications (p = 0.04).

Conclusion

Vascular events with the use of IABP are common but in our study, not significantly associated with a higher mortality. Treatment with GP IIb/IIIa-antagonists is associated with a higher risk of vascular events.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
经主动脉内球囊泵(IABP)支持的心源性休克患者GP IIb/ iia拮抗剂导致血管并发症的风险增加
背景:在心源性休克患者中,常规使用diabp来支持冠状动脉血流和体循环。我们的目的是探讨在这种情况下使用IABP相关的血管并发症的发生率及其对死亡率的影响。方法对2002 ~ 2013年连续204例经IAPB治疗心源性休克患者的血管并发症及IAPB植入后30天内的死亡率进行分析。主要终点是严重出血(timi定义:颅内出血,血红蛋白(Hb)丢失;5 g/dl或红细胞压积(PCV);15%)、有治疗后果的血管并发症(静脉血栓、动脉栓塞)和中风。结果80例(39%)患者在IABP植入后30 d内死亡。42例(21%)患者发生血管并发症:26例(占所有并发症的62%)患者出现严重出血,13例(31%)患者患有静脉血栓形成或动脉栓塞,3例(7%)患者患有中风。25%的患者死于血管并发症。心源性休克的发生率为17.7% (p = 0.22)。多因素分析显示,糖蛋白(GP) IIb/IIIa-抑制剂治疗是血管并发症发生的独立危险因素(p = 0.04)。结论:血管事件与IABP的使用是常见的,但在我们的研究中,与更高的死亡率没有显著相关。使用GP IIb/ iiia拮抗剂治疗与血管事件的高风险相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Paclitaxel eluting balloon plus spot bare metal stenting for diffuse and very long coronary disease. (PEB-long pilot study) High prevalence of ST-elevation, early repolarization, and left ventricular hypertrophy during the eligibility assessment for an HIV vaccine trial in young, healthy Tanzanians Using a personalized decision support algorithm for dosing in warfarin treatment: A randomised controlled trial Dose and response to cocoa (DARC): A randomized double-blind controlled trial Massage therapy reduces pain and anxiety after cardiac surgery: A systematic review and meta-analysis of randomized clinical trials
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1